SM
KURA icon

SG3 Management’s Kura Oncology KURA Stock Holding History

SG3 Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-35,000
Closed -$490K – 1191
2021
Q4 		$490K Buy
35,000
+20,000
+133% +$324K 0.01% 628
2021
Q3 		$281K Sell
15,000
-20,000
-57% -$377K 0.01% 716
2021
Q2 		$730K Buy
+35,000
New +$869K 0.03% 568

Other funds holding KURA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

SG3 Management's KURA Position: Q4 2020 in Review

SG3 Management sold out of Kura Oncology (KURA) in Q4 2020, closing a stake of 5,000 shares — an estimated $176K sold.

SG3 Management first reported a position in KURA in Q3 2020 and held it in 1 quarter. The position peaked at $153K in Q3 2020. 198 funds tracked by Wall St. Rank hold KURA as of Q4 2020.

  • SG3 Management reported no remaining Kura Oncology position as of Q4 2020 after selling out during the quarter.
  • SG3 Management sold 5,000 Kura Oncology shares in Q4 2020, an estimated $176K.
  • SG3 Management first reported a position in Kura Oncology in Q3 2020 and held it in 1 quarter.
  • SG3 Management's Kura Oncology position peaked at $153K in Q3 2020.
  • 198 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2020.

Based on SG3 Management's 13F filing for Q4 2020, filed 16 Feb 2021.